Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03939533
Other study ID # SCGAM-06
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 17, 2019
Est. completion date January 3, 2022

Study information

Verified date November 2023
Source Octapharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CLINICAL PHASE 3 STUDY TO MONITOR THE SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (CUTAQUIG®) ADMINISTERED AT MODIFIED DOSING REGIMENS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date January 3, 2022
Est. primary completion date January 3, 2022
Accepts healthy volunteers No
Gender All
Age group 2 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age =2 years and =75 years. 2. Confirmed diagnosis of primary immunodeficiency (PI) disease as defined by the European Society for Immunodeficiencies and Pan American Group for Immunodeficiency and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. Note: The exact type of PI disease will be recorded. 3. Established on a consistent or stable mg/kg dose of any SCIG treatment for a minimum of 3 months prior to Screening. Note: patients entering Cohort 3 must be on weekly SCIG infusions for a minimum of 12 weeks. 4. Availability of the Immunoglobulin G (IgG) trough levels of 2 previous SCIG infusions within 1 year of Screening, with 1 trough level obtained within 3 months prior to enrollment, and maintenance of trough serum IgG levels =5.0 g/L in 2 previous infusions. Patients with no prior IgG trough level within 3 months prior to enrollment may use the Screening IgG trough level as their 2nd reading. 5. Voluntarily given, fully informed signed informed consent. For patients under the legal age of consent, voluntarily given, fully-informed, signed informed consent will be provided by patient's parent or legal guardian, and assent will be provided by patient (per age-appropriate Institutional Review Board [IRB] requirements). 6. Females of childbearing potential, who are not nursing and have no plans for pregnancy during the course of the study, have been using at least 1 acceptable form of birth control for a minimum of 30 days prior to the Screening visit and must agree to use at least 1 acceptable method of contraception for 30 days after the last dose of CUTAQUIG. Acceptable methods include: intrauterine device (IUD), hormonal contraception, male or female condom, spermicide gel, diaphragm, sponge, cervical cap, or abstinence. 7. For female patients of child-bearing potential, a negative result in a urine pregnancy test conducted at the Screening visit. 8. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study. Exclusion Criteria: 1. Evidence of active infection within 4 weeks of Screening or during the Screening Period. 2. Current or clinically-significant history of any cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological (excluding PI), hematologic, and/or psychiatric disorder(s), or a history of any other illness that, in the opinion of the Investigator, might confound the results of the study, or pose additional risk to the patient by participation in the study. 3. Known history of adverse reactions to immunoglobulin A (IgA) in other products. 4. Body mass index (BMI) >40 kg/m2 for patients entering Cohort 2 or Cohort 3. There are no BMI restrictions for Cohort 1. 5. Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products, or any component of the investigational product (such as Polysorbate 80). 6. Requirement of any routine premedication for IgG administration. 7. History of malignancies of lymphoid cells and immunodeficiency with lymphoma. 8. Severe liver function impairment (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >3 times above upper limit of normal). 9. Known protein-losing enteropathies or clinically significant proteinuria. 10. Presence of renal function impairment (creatine >120 µM/L or creatinine >1.35 mg/dL), or predisposition for acute renal failure (eg, any degree of preexisting renal insufficiency or routine treatment with known nephritic drugs). 11. Treatment with oral or parenteral steroids for =30 days, or when given intermittently or as bolus at daily doses =0.15 mg/kg when taken within 30 days of Screening. Note: Short or intermittent courses of steroids (ie, a steroid burst) of >0.15 mg/kg/day is allowed for treatment of a short-term condition such as an asthma exacerbation. 12. Treatment with immunosuppressive or immunomodulatory drugs (except Omalizumab). 13. Use of HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase) within 3 months prior to first CUTAQUIG infusion. 14. Live viral vaccination (such as measles, rubella, mumps, and varicella) within 2 months prior to first CUTAQUIG infusion. 15. Exposure to blood or any blood product or derivative, other than subcutaneous IgG used for regular PI disease treatment, within 3 months before the first CUTAQUIG infusion. 16. Treatment with any investigational medicinal product within 3 months prior to first CUTAQUIG infusion. Note: Patients participating in Study SCGAM-03 will be allowed to enter this study without the 3-month waiting period for an Investigational Product. Patients receiving another SCIG product within 3 months prior to the first CUTAQUIG infusion may be considered for enrollment after Sponsor approval. 17. Presence of any condition that is likely to interfere with the evaluation of CUTAQUIG or satisfactory conduct of the trial. 18. Known or suspected to abuse alcohol, drugs, psychotropic agents, or other chemicals within the past 12 months prior to first CUTAQUIG infusion. 19. Known active or chronic hepatitis B, hepatitis C, or HIV infection. Past hepatitis B or hepatitis C infection that has been cured is allowed.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CUTAQUIG
Human normal immunoglobulin

Locations

Country Name City State
United States Octapharma Research Site Albany Georgia
United States Octapharma Research Site Asheville North Carolina
United States Octapharma Research Site Bellingham Washington
United States Octapharma Research Site Centennial Colorado
United States Octapharma Research Site Chevy Chase Maryland
United States Octapharma Research Site Cincinnati Ohio
United States Octapharma Research Site Dallas Texas
United States Octapharma Research Site Irvine California
United States Octapharma Research Site Louisville Kentucky
United States Octapharma Research Site Mayfield Ohio
United States Octapharma Research Site North Palm Beach Florida
United States Octapharma Research Site Papillion Nebraska
United States Octapharma Research Site Pittsburgh Pennsylvania
United States Octapharma Research Site Saint Louis Missouri
United States Octapharma Research Site Saint Petersburg Florida
United States Octapharma Research Site Santa Barbara California
United States Octapharma Research Site Scottsdale Arizona
United States Octapharma Research Site Toledo Ohio

Sponsors (1)

Lead Sponsor Collaborator
Octapharma

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary IgG Trough Levels From Baseline to End of Study (28 Weeks) Mean change from baseline in individual total IgG trough levels in cohort 3 from weekly infusions to end of study (28 weeks) every other week infusions, and for cohort 1 and cohort 2 (weekly infusions) change from baseline through study completion (28 weeks) Through study completion, up to 28 weeks
Secondary Serious Bacterial Infection Rates Number of subjects who reported SBIs during the study Through study completion, up to 28 weeks
Secondary Time to Resolution of Infections The amount of days it took for infectious disease occurrence and resolution for subjects Through study completion, 28 weeks
Secondary Antibiotic Usage Amount of subjects treated with antibiotics during the study Through study completion, up to 28 weeks
Secondary Number of Antibiotic Treatment Episodes Annualized Total number of treatment episodes annualized calculated as the sum of all unique episodes of antibiotics of all subjects from first dose day of cutaquig to last study visit/number of person years exposure Through study completion, up to 28 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03266640 - Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) Phase 2
Recruiting NCT03266627 - Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection Phase 2
Completed NCT01859754 - Octagam 5% Versus Comparator Post Marketing Trial
Recruiting NCT03148028 - Immunological Characteristics of Patients With PID and IBD N/A
Active, not recruiting NCT04354818 - Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
Completed NCT03988426 - Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases Phase 3
Completed NCT01888484 - Study of Octanorm Subcutaneous IG in Patients With PID Phase 3
Completed NCT01131858 - Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency Phase 1/Phase 2
Completed NCT03211689 - The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease N/A
Terminated NCT01883921 - Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)
Recruiting NCT03266653 - EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection Phase 2
Completed NCT02327351 - TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID Phase 2/Phase 3
Completed NCT03618147 - Primary Immunodeficiency in Kuwait
Recruiting NCT04197596 - Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) Phase 1/Phase 2
Recruiting NCT03422614 - Pathophysiology of Inborn Immunodeficiencies N/A
Completed NCT02888535 - Intensive Care Unit and Secondary and Primary Immune Deficiency
Recruiting NCT04232085 - Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide Phase 2
Active, not recruiting NCT03037359 - A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
Completed NCT03069079 - Investigation of Dental Health in Children With Neutrophil Defects: A Clinical Study N/A
Recruiting NCT03414528 - Identification of New Inborn Errors of Immunity N/A